216 related articles for article (PubMed ID: 23625925)
1. Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.
Stehle F; Schulz K; Fahldieck C; Kalich J; Lichtenfels R; Riemann D; Seliger B
J Biol Chem; 2013 Jun; 288(23):16334-16347. PubMed ID: 23625925
[TBL] [Abstract][Full Text] [Related]
2. Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion.
Du Four S; Maenhout SK; Benteyn D; De Keersmaecker B; Duerinck J; Thielemans K; Neyns B; Aerts JL
Cancer Immunol Immunother; 2016 Jun; 65(6):727-40. PubMed ID: 27098427
[TBL] [Abstract][Full Text] [Related]
3. The multi-receptor inhibitor axitinib reverses tumor-induced immunosuppression and potentiates treatment with immune-modulatory antibodies in preclinical murine models.
Läubli H; Müller P; D'Amico L; Buchi M; Kashyap AS; Zippelius A
Cancer Immunol Immunother; 2018 May; 67(5):815-824. PubMed ID: 29487979
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of JNK2 and JNK3 by JNK inhibitor IX induces prometaphase arrest-dependent apoptotic cell death in human Jurkat T cells.
Jang WY; Lee JY; Lee ST; Jun do Y; Kim YH
Biochem Biophys Res Commun; 2014 Sep; 452(3):845-51. PubMed ID: 25218503
[TBL] [Abstract][Full Text] [Related]
5. Resistance to the tyrosine kinase inhibitor axitinib is associated with increased glucose metabolism in pancreatic adenocarcinoma.
Hudson CD; Hagemann T; Mather SJ; Avril N
Cell Death Dis; 2014 Apr; 5(4):e1160. PubMed ID: 24722285
[TBL] [Abstract][Full Text] [Related]
6. Downregulation of Mcl-1 through inhibition of translation contributes to benzyl isothiocyanate-induced cell cycle arrest and apoptosis in human leukemia cells.
Zhou T; Li G; Cao B; Liu L; Cheng Q; Kong H; Shan C; Huang X; Chen J; Gao N
Cell Death Dis; 2013 Feb; 4(2):e515. PubMed ID: 23449451
[TBL] [Abstract][Full Text] [Related]
7. Axitinib induces senescence-associated cell death and necrosis in glioma cell lines: The proteasome inhibitor, bortezomib, potentiates axitinib-induced cytotoxicity in a p21(Waf/Cip1) dependent manner.
Morelli MB; Amantini C; Nabissi M; Cardinali C; Santoni M; Bernardini G; Santoni A; Santoni G
Oncotarget; 2017 Jan; 8(2):3380-3395. PubMed ID: 27926485
[TBL] [Abstract][Full Text] [Related]
8. The VEGF-Receptor Inhibitor Axitinib Impairs Dendritic Cell Phenotype and Function.
Heine A; Held SA; Daecke SN; Riethausen K; Kotthoff P; Flores C; Kurts C; Brossart P
PLoS One; 2015; 10(6):e0128897. PubMed ID: 26042424
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanism mediating cytotoxic activity of axitinib in sunitinib-resistant human renal cell carcinoma cells.
Miyazaki A; Miyake H; Fujisawa M
Clin Transl Oncol; 2016 Sep; 18(9):893-900. PubMed ID: 26597115
[TBL] [Abstract][Full Text] [Related]
10. [Multikinase inhibitors as a new approach in neovascular age-related macular degeneration (AMD) treatment: in vitro safety evaluations of axitinib, pazopanib and sorafenib for intraocular use].
Thiele S; Liegl RG; König S; Siedlecki J; Langer J; Eibl K; Haritoglou C; Kampik A; Kernt M
Klin Monbl Augenheilkd; 2013 Mar; 230(3):247-54. PubMed ID: 23508753
[TBL] [Abstract][Full Text] [Related]
11. Folate-Hapten-Mediated Immunotherapy Synergizes with Vascular Endothelial Growth Factor Receptor Inhibitors in Treating Murine Models of Cancer.
Bandara NA; Bates CD; Lu Y; Hoylman EK; Low PS
Mol Cancer Ther; 2017 Mar; 16(3):461-468. PubMed ID: 27980109
[TBL] [Abstract][Full Text] [Related]
12. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
Daimon M; Kato T; Kaino W; Takase K; Karasawa S; Wada K; Kameda W; Susa S; Oizumi T; Tomita Y; Kato T
Jpn J Clin Oncol; 2012 Aug; 42(8):742-7. PubMed ID: 22628612
[TBL] [Abstract][Full Text] [Related]
13. Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.
Bose A; Lowe DB; Rao A; Storkus WJ
Melanoma Res; 2012 Jun; 22(3):236-43. PubMed ID: 22504156
[TBL] [Abstract][Full Text] [Related]
14. Helenalin suppresses essential immune functions of activated CD4+ T cells by multiple mechanisms.
Berges C; Fuchs D; Opelz G; Daniel V; Naujokat C
Mol Immunol; 2009 Sep; 46(15):2892-901. PubMed ID: 19656571
[TBL] [Abstract][Full Text] [Related]
15. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
16. Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation.
Pemovska T; Johnson E; Kontro M; Repasky GA; Chen J; Wells P; Cronin CN; McTigue M; Kallioniemi O; Porkka K; Murray BW; Wennerberg K
Nature; 2015 Mar; 519(7541):102-5. PubMed ID: 25686603
[TBL] [Abstract][Full Text] [Related]
17. Axitinib induces DNA damage response leading to senescence, mitotic catastrophe, and increased NK cell recognition in human renal carcinoma cells.
Morelli MB; Amantini C; Santoni M; Soriani A; Nabissi M; Cardinali C; Santoni A; Santoni G
Oncotarget; 2015 Nov; 6(34):36245-59. PubMed ID: 26474283
[TBL] [Abstract][Full Text] [Related]
18. Induction of G2/M Phase Arrest by Diosgenin via Activation of Chk1 Kinase and Cdc25C Regulatory Pathways to Promote Apoptosis in Human Breast Cancer Cells.
Liao WL; Lin JY; Shieh JC; Yeh HF; Hsieh YH; Cheng YC; Lee HJ; Shen CY; Cheng CW
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31881805
[TBL] [Abstract][Full Text] [Related]
19. The European Medicines Agency approval of axitinib (Inlyta) for the treatment of advanced renal cell carcinoma after failure of prior treatment with sunitinib or a cytokine: summary of the scientific assessment of the committee for medicinal products for human use.
Tzogani K; Skibeli V; Westgaard I; Dalhus M; Thoresen H; Slot KB; Damkier P; Hofland K; Borregaard J; Ersbøll J; Salmonson T; Pieters R; Sylvester R; Mickisch G; Bergh J; Pignatti F
Oncologist; 2015 Feb; 20(2):196-201. PubMed ID: 25616431
[TBL] [Abstract][Full Text] [Related]
20. MC37, a new mono-carbonyl curcumin analog, induces G2/M cell cycle arrest and mitochondria-mediated apoptosis in human colorectal cancer cells.
Liang B; Liu Z; Cao Y; Zhu C; Zuo Y; Huang L; Wen G; Shang N; Chen Y; Yue X; Du J; Li B; Zhou B; Bu X
Eur J Pharmacol; 2017 Feb; 796():139-148. PubMed ID: 28024945
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]